These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

91 related items for PubMed ID: 11607855

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Outpatient treatment of pulmonary embolism with dalteparin.
    Kovacs MJ, Anderson D, Morrow B, Gray L, Touchie D, Wells PS.
    Thromb Haemost; 2000 Feb; 83(2):209-11. PubMed ID: 10739374
    [Abstract] [Full Text] [Related]

  • 4. Use of low molecular weight heparin (dalteparin), once daily, for the treatment of deep vein thrombosis. A feasibility and health economic study in an outpatient setting. Swedish Venous Thrombosis Dalteparin Trial Group.
    Lindmarker P, Holmström M.
    J Intern Med; 1996 Dec; 240(6):395-401. PubMed ID: 9010387
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Compression and walking versus bed rest in the treatment of proximal deep venous thrombosis with low molecular weight heparin.
    Partsch H, Blättler W.
    J Vasc Surg; 2000 Nov; 32(5):861-9. PubMed ID: 11054217
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
    Lee AY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, Rickles FR, Julian JA, Haley S, Kovacs MJ, Gent M, Randomized Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer (CLOT) Investigators.
    N Engl J Med; 2003 Jul 10; 349(2):146-53. PubMed ID: 12853587
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. A randomized trial comparing 2 low-molecular-weight heparins for the outpatient treatment of deep vein thrombosis and pulmonary embolism.
    Wells PS, Anderson DR, Rodger MA, Forgie MA, Florack P, Touchie D, Morrow B, Gray L, O'Rourke K, Wells G, Kovacs J, Kovacs MJ.
    Arch Intern Med; 2005 Apr 11; 165(7):733-8. PubMed ID: 15824291
    [Abstract] [Full Text] [Related]

  • 12. Dalteparin versus unfractionated heparin in critically ill patients.
    PROTECT Investigators for the Canadian Critical Care Trials Group and the Australian and New Zealand Intensive Care Society Clinical Trials Group, Cook D, Meade M, Guyatt G, Walter S, Heels-Ansdell D, Warkentin TE, Zytaruk N, Crowther M, Geerts W, Cooper DJ, Vallance S, Qushmaq I, Rocha M, Berwanger O, Vlahakis NE.
    N Engl J Med; 2011 Apr 07; 364(14):1305-14. PubMed ID: 21417952
    [Abstract] [Full Text] [Related]

  • 13. A fixed-dose combination of low molecular weight heparin with dihydroergotamine versus adjusted-dose unfractionated heparin in the prevention of deep-vein thrombosis after total hip replacement.
    Horbach T, Wolf H, Michaelis HC, Wagner W, Hoffmann A, Schmidt A, Beck H.
    Thromb Haemost; 1996 Feb 07; 75(2):246-50. PubMed ID: 8815569
    [Abstract] [Full Text] [Related]

  • 14. [Evolution in the pharmacological treatment of venous thrombosis according to evidence-based medicine].
    Manganaro A, Giannino D, Lembo D, Bruni F, Consolo F.
    Minerva Cardioangiol; 2000 Dec 07; 48(12 Suppl 1):41-51. PubMed ID: 11253339
    [Abstract] [Full Text] [Related]

  • 15. Out-patient treatment of acute deep vein thrombosis.
    Mattiasson I, Berntorp E, Bornhov S, Lagerstedt C, Lethagen S, Persson J, Timberg I, Torstensson I.
    Int Angiol; 1998 Sep 07; 17(3):146-50. PubMed ID: 9821026
    [Abstract] [Full Text] [Related]

  • 16. Prolonged thromboprophylaxis with Dalteparin during immobilization after ankle fracture surgery: a randomized placebo-controlled, double-blind study.
    Lapidus LJ, Ponzer S, Elvin A, Levander C, Lärfars G, Rosfors S, de Bri E.
    Acta Orthop; 2007 Aug 07; 78(4):528-35. PubMed ID: 17966008
    [Abstract] [Full Text] [Related]

  • 17. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients.
    Leizorovicz A, Cohen AT, Turpie AG, Olsson CG, Vaitkus PT, Goldhaber SZ, PREVENT Medical Thromboprophylaxis Study Group.
    Circulation; 2004 Aug 17; 110(7):874-9. PubMed ID: 15289368
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and safety of prolonged thromboprophylaxis with a low molecular weight heparin (dalteparin) after total hip arthroplasty--the Danish Prolonged Prophylaxis (DaPP) Study.
    Lassen MR, Borris LC, Anderson BS, Jensen HP, Skejø Bro HP, Andersen G, Petersen AO, Siem P, Hørlyck E, Jensen BV, Thomsen PB, Hansen BR, Erin-Madsen J, Møller JC, Rotwitt L, Christensen F, Nielsen JB, Jørgensen PS, Paaske B, Tørholm C, Hvidt P, Jensen NK, Nielsen AB, Appelquist E, Tjalve E.
    Thromb Res; 1998 Mar 15; 89(6):281-7. PubMed ID: 9669750
    [Abstract] [Full Text] [Related]

  • 19. Practicability and quality of outpatient management of acute deep venous thrombosis.
    Blättler W, Kreis N, Blättler IK.
    J Vasc Surg; 2000 Nov 15; 32(5):855-60. PubMed ID: 11054216
    [Abstract] [Full Text] [Related]

  • 20. [Treatment of thrombosis with low-molecular-weight heparin. Comparison of body weight-adjusted and fixed dosage].
    Harenberg J.
    Med Klin (Munich); 2003 Sep 15; 98(9):493-8. PubMed ID: 14551706
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.